Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.

Area of Science:

• Neuroimmunology
• Vascular Biology
• Multiple Sclerosis Pathogenesis

Background:

• Endothelial activation is crucial in multiple sclerosis (MS) pathogenesis.
• Interferon beta-1b (IFNB-1b) is known to modulate endothelial activation in relapsing-remitting MS (RRMS).
• The effect of IFNB-1b on endothelial activation in primary progressive MS (PPMS) remains unproven.

Purpose of the Study:

• To investigate the pharmacodynamic effects of IFNB-1b on endothelial activation markers in PPMS patients.
• To analyze serum concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1) and sE-selectin during IFNB-1b treatment.

Main Methods:

• Longitudinal analysis of serum sVCAM-1 and sE-selectin in 18 PPMS patients.
• Measurements taken before, during, and after 12 months of IFNB-1b treatment.
• Correlation analysis with flu-like symptoms, infections, and neutralizing antibodies to IFNB-1b.

Main Results:

• A significant, early, and sustained increase in serum sVCAM-1 was observed during IFNB-1b therapy (P < 0.0001).
• Higher sVCAM-1 levels were associated with IFNB-1b-induced flu-like symptoms and infections.
• Lower sVCAM-1 levels correlated with the presence of neutralizing antibodies to IFNB-1b.

Conclusions:

• IFNB-1b modulates the adhesion cascade in PPMS patients, mirroring effects seen in RRMS.
• The findings suggest a similar pharmacodynamic action of IFNB-1b in both MS subtypes.
• Further randomized controlled trials are necessary to establish the clinical efficacy of IFNB-1b in PPMS.